TheEdgeResearch
Home / Stocks / UCBJY

UCB S.A. (UCBJY)

OTC Healthcare Biotechnology
$151.67 ▼ -2.24%
Market Cap
$57.74B
Sector
Healthcare
Industry
Biotechnology
Beta
0.20
52-Wk Range
110.55-168.76
CEO
Jean-Christophe Tellier
Country
BE
Currency
USD

UCB S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Brussels, BU, BE. The stock last traded at $151.67, down 2.24% on the session, giving a market capitalisation of $57.74B. On trailing twelve-month figures it carries a trailing P/E of 24.21, a net margin of 25.7%. Its beta of 0.20 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
24.21
Price / Sales
6.25
Price / Book
4.56
EV / EBITDA
22.72
Gross margin
76.2%
Operating margin
31.2%
Net margin
25.7%
Return on equity
—
Debt / equity
0.31
Current ratio
1.20
Dividend yield
0.5%
Payout ratio
12.6%
Company profile
Exchange
Other OTC
Employees
10,117
IPO date
2012-08-03
Headquarters
Brussels, BU, BE
About UCB S.A.

UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.

Comparable companies

UCB S.A. is most often compared with the following Healthcare names:

ABBVAMGNANABARGXBIIBHLBBFIFRXJAZZNBIXNRIX
More research on UCBJY
UCBJY technical analysis UCBJY TheEdge Score Compare against peers
Open full interactive analysis & DCF →